MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

Gut, Год журнала: 2024, Номер unknown, С. gutjnl - 330595

Опубликована: Янв. 16, 2024

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic globally and is currently estimated to affect up 38% of global adult population. NAFLD a multisystem where systemic insulin resistance related metabolic dysfunction play pathogenic role in development its relevant liver-related morbidities (cirrhosis, failure hepatocellular carcinoma) extrahepatic complications, such as cardiovascular (CVD), type 2 diabetes mellitus, kidney disease, certain types cancers. In 2023, three large multinational associations proposed that dysfunction-associated steatotic (MASLD) should replace term NAFLD; name chosen non-alcoholic steatohepatitis was (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between MASLD definitions—that is, ~99% individuals with meet criteria. this narrative review, we provide overview literature on (a) recent data risk developing CVD malignant (b) underlying mechanisms by which (and factors strongly linked MASLD) may increase these complications (c) diagnosis assessment potential treatments reduce people or MASH.

Язык: Английский

---

Steatotic liver disease

The Lancet, Год журнала: 2024, Номер 404(10464), С. 1761 - 1778

Опубликована: Ноя. 1, 2024

Язык: Английский

---

Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence

Liver International, Год журнала: 2024, Номер 44(8), С. 1762 - 1767

Опубликована: Апрель 10, 2024

A recent Delphi consensus proposed a new definition for metabolic dysfunction associated steatotic liver disease (MASLD) and introduced entity called MetALD, condition in which (SLD), moderate alcohol intake coexist. Given the limited available data on prognostic implications of these entities, we performed systematic review meta-analysis cohort studies to evaluate association MASLD MetALD with hard clinical outcomes. We included 5 total 9 824 047 participants. Compared participants without SLD, increased rates all-cause mortality incident cardiovascular were present both MetALD. Moreover, was also significantly higher risks cancer-related (n = 2 studies, random-effects HR 2.10, 95% CI 1.35-3.28) 3 1.17, 1.12-1.22). Although preliminary, evidence indicates more unfavourable prognosis patients compared those MASLD.

Язык: Английский

---

Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(4), С. 1158 - 1158

Опубликована: Фев. 19, 2024

This cross-sectional study examined the prevalence and characteristics of steatotic liver disease (SLD) based on a recently introduced nomenclature in Japanese health checkup population. SLD was evaluated using ultrasonography, participants were categorized into metabolic dysfunction-associated (MASLD), dysfunction alcohol associated (MetALD), alcohol-associated/related (ALD), cryptogenic groups. The subclasses assessed, subgroup analyses conducted for non-obese (body mass index [BMI] ≤ 25 kg/m2) lean (BMI 23 populations. Among 694 participants, with median age 47 years comprising 54% males, MASLD, MetALD, ALD, 26%, 2%, 1%, respectively. A remarkable difference observed according to age, sex, BMI. Subgroup revealed heterogeneous demographic, clinical, biochemical parameters between categories. Individuals MetALD had higher gamma-glutamyl transferase levels, lower platelet counts, fibrosis-4 than did those MASLD. Furthermore, MASLD 13% 6%, provides preliminary information new

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Cardiovascular Diabetology, Год журнала: 2024, Номер 23(1)

Опубликована: Сен. 28, 2024

Язык: Английский

---

Systemic metabolic abnormalities: Key drivers of complications and mortality in MASLD

Journal of Hepatology, Год журнала: 2024, Номер 80(6), С. e246 - e248

Опубликована: Фев. 2, 2024

Язык: Английский

---

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Авг. 26, 2024

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important public health problem owing to its high prevalence and associated morbidity mortality secondary progressive cardiovascular events. Resmetirom, a selective thyroid hormone receptor-β agonist has been developed as therapeutic modality for MASLD. This systematic review meta-analysis aimed evaluate the effectiveness safety of resmetirom compared placebo in treatment Eligible studies were systematically identified by screening PubMed, Scopus, Web Science, Cochrane library, Embase, ClinicalTrials.gov from 2014 2024. Only randomized controlled trials comparing efficacy MASLD against included analysis. Meta-analysis was performed using RevMan 5.4 software. Four with low risk bias involving total 2359 participants identified. The metanalysis only three clinical 2234 participants. A significant reduction MRI-proton density fat fraction (MRI-PDFF) 80 mg Resmetirom that [SMD − 27.74 (95% CI 32.05 32.42), p < 0.00001] at 36–52 weeks well 12–16 30.92 36.44 25.40), 0.00001]. With 100 dose 36.05 40.67 31.43), 36.89 40.73 33.05), observed. LDL-c triglyceride, lipoproteins. enzymes. There FT4 increase SHBG sex steroids placebo. no major difference overall emergent adverse events [OR 1.55 0.84 2.87), 1.13 0.78 1.63), doses However, gastrointestinal diarrhoea nausea occurred ≥ 10% group 12 week. showed modest treating MRI-PDFF, LDL-c, lipoproteins, enzymes NASH biomarkers without concerns. Larger long-term RCTs may further confirm this promising outcomes use

Язык: Английский

---

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Clinical and Molecular Hepatology, Год журнала: 2024, Номер 30(3), С. 577 - 579

Опубликована: Март 6, 2024

Язык: Английский

---

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

Seminars in Liver Disease, Год журнала: 2024, Номер 44(01), С. 035 - 042

Опубликована: Фев. 1, 2024

In June 2023, under the patronage of American Association for Study Liver Disease, European Liver, and Asociación Latinoamericana para el Estudio del Hígado with involvement 236 participants from around world, a new nomenclature definition nonalcoholic fatty liver disease (NAFLD) has been proposed. Metabolic dysfunction-associated steatotic (MASLD) was defined as presence hepatic steatosis at least one cardiometabolic risk factors alcohol intake less than 140 g/wk women 210 men no other causes steatosis. A entity called combined metabolic dysfunction- alcohol-associated (MetALD) created outside pure MASLD patients dysfunction greater that allowed (i.e., 140–350 210–420 men). Recent studies have confirmed 95% overlap between NAFLD diagnostic criteria. Natural history, biomarkers, thresholds in MetALD group remains to be studied validated.

Язык: Английский

---

ZBP1-mediated apoptosis and inflammation exacerbate steatotic liver ischemia-reperfusion injury

Journal of Clinical Investigation, Год журнала: 2024, Номер 134(13)

Опубликована: Май 14, 2024

There is increasing need to expand availability of donor liver grafts, including steatotic livers. However, the current use grafts in transplantation less acceptable due their higher susceptibility ischemia-reperfusion (I/R) injury. To investigate mechanism underlying I/R injury, we detected cell death markers and inflammation clinical livers animal models. We found that caspase-8-mediated hepatic apoptosis activated I/R. ablation caspase-8 only slightly mitigated injury without affecting inflammation. further demonstrated RIPK1 kinase induces both death-independent Inhibition significantly protects against by alleviating Additionally, activation induced Z-DNA binding protein 1 (ZBP1) but not canonical TNFα pathway during Deletion ZBP1 substantially decreases Mechanistically, amplified palmitic acid-activated JNK Upon I/R, excessive reactive oxygen species trigger inducing its aggregation independent Z-nucleic acids sensing action livers, leading subsequent aggravation Thus, ZBP1-mediated RIPK1-driven exacerbate which could be targeted protect transplantation.

Язык: Английский

---